Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
Tag: Semaglutide
Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility
Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility: Mechanisms, Evidence, and Clinical Implications Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for the treatment of type 2 diabetes mellitus and obesity. Increasingly, reports suggest a possible association between GLP-1 RA use and
Emerging and Approved Therapeutic Peptides: Mechanisms, Clinical Uses
Emerging and Approved Therapeutic Peptides: Mechanisms, Clinical Uses, Safety Profiles, and Regulatory Status Across Health Conditions Abstract Therapeutic peptides represent a rapidly growing class of pharmaceutical agents that bridge the gap between small molecule drugs and large protein therapeutics. This paper examines the
GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis
Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction
Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction Overview Osteoarthritis (OA) is a widespread degenerative joint condition. While the influence of obesity on OA is well-established, the effect of semaglutide on OA remains less understood. The objective was to evaluate the effect of semaglutide on the risk of OA among patients with
